Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II

Vieira, Raquel; Souto, Selma B.; Sánchez-López, Elena; Machado, Ana López; Severino, Patrícia; Jose, Sajan; Santini, Antonello; Silva, Amélia M.; Fortuna, Ana; García, María L.; Souto, Eliana B.

doi:10.3390/jcm8091332

Cited by 51 publications

(33 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The epidemic metabolic disorder, diabetes mellitus (DM) is characterized by high blood glucose where the patient cannot produce adequate insulin, or body cells do not respond to glucose produced by β-cells in the pancreas. Many people have diabetes all over the world [1][2][3], and the number is increasing at an alarming rate. According to the World Health Organization, diabetes causes 1.5 million deaths each year worldwide, being one of the most recurrent cause of mortality in developed countries [2].…”

Section: Introductionmentioning

confidence: 99%

Biological efficacy of zinc oxide nanoparticles against diabetes: a preliminary study conducted in mice

et al. 2020

View full text Add to dashboard Cite

The antidiabetic, hypoglycemic and oral glucose tolerance test (OGTT) activities of zinc oxide nanoparticles (ZnONPs) were assessed in mice. ZnONPs were prepared by reacting Zn(NO3)2.6H2O and NaOH solution at 70°C with continuous stirring and then characterized by transmission electron microscopy (TEM) and scanning electron microscopy (SEM) techniques. Diabetes was induced by the intraperitoneal injection of streptozotocin (STZ) in mice, and then the blood glucose levels were determined by the glucose oxidase method. The experimental results revealed that ZnONPs suggestively (p<0.001) declined the blood glucose levels (39.79%), while these reductions were 38.78% for the cotreatment of ZnONPs and insulin, and 48.60% for insulin, respectively. In the hypoglycemic study, ZnONPs (8 and 14 mg/kg b.w) reduced approximately 25.13 and 29.15% of blood glucose levels, respectively. A similar reduction was found in the OGTT test, which is also a dose- and time-dependent manner. Overall, ZnONPs possess a potential antidiabetic activity, which could be validated by further mechanistic studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Biological efficacy of zinc oxide nanoparticles against diabetes: a preliminary study conducted in mice

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Nanonutraceutics could be an important tool useful among the strategies adopted in managing health conditions, particularly tailored to patients who are not eligible for a conventional pharmacological therapy. Studies on follow up, use, and compliance of pharmaceuticals reported in the area [98][99][100][101], as well as communication strategies and assessment [102], should be extended also to nutraceuticals and carried out in view of exploiting the field to different health conditions, e.g., the ones clustered in the so-called "metabolic syndrome", which includes conditions ranging from obesity to dysmetabolism [103][104][105]. These latter are often related to the food intake/dietary habits of each person.…”

Section: From Nanopharmaceutics To Nanonutraceutics: a Bet For The Fumentioning

confidence: 99%

Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods

et al. 2020

View full text Add to dashboard Cite

Due the implementation of nanotechnologies in the pharmaceutical industry over the last few decades, new type of cutting-edge formulations-nanopharmaceutics-have been proposed. These comprise pharmaceutical products at the nanoscale, developed from different types of materials with the purpose to, e.g., overcome solubility problems of poorly water-soluble drugs, the pharmacokinetic and pharmacodynamic profiles of known drugs but also of new biomolecules, to modify the release profile of loaded compounds, or to decrease the risk of toxicity by providing site-specific delivery reducing the systemic distribution and thus adverse side effects. To succeed with the development of a nanopharmaceutical formulation, it is first necessary to analyze the type of drug which is to be encapsulated, select the type matrix to load it (e.g., polymers, lipids, polysaccharides, proteins, metals), followed by the production procedure. Together these elements have to be compatible with the administration route. To be launched onto the market, the selected production method has to be scaled-up, and quality assurance implemented for the product to reach clinical trials, during which in vivo performance is evaluated. Regulatory issues concerning nanopharmaceutics still require expertise for harmonizing legislation and a clear understanding of clinically compliant production methods. The first part of this study addressing "Nanopharmaceutics: Part I-Clinical trials legislation and Good Manufacturing Practices (GMP) of nanotherapeutics in the EU" has been published in Pharmaceutics. This second part complements the study with the discussion about the production scales and clinically compliant production methods of nanopharmaceutics.Nanomaterials 2020, 10, 455 2 of 16 funding opportunities within Member States, Associated Countries and Third Countries. The strategic plan for the next Horizon Europe framework programme has clearly set nanomedicines and advanced therapies as priorities. To succeed, the nanoproduct needs to be manufacturable at large scale and its quality assured in order to reach clinical trials. The topic is indeed of high scientific interest considering the number of scientific papers dealing with clinical trials and nanoparticles over the last twenty years (Figure 1). Nanomaterials 2020, 10, x FOR PEER REVIEW 2 of 17European Commission aims to lead innovation towards the development of these nanopharmaceutics by launching several funding opportunities within Member States, Associated Countries and Third Countries. The strategic plan for the next Horizon Europe framework programme has clearly set nanomedicines and advanced therapies as priorities. To succeed, the nanoproduct needs to be manufacturable at large scale and its quality assured in order to reach clinical trials. The topic is indeed of high scientific interest considering the number of scientific papers dealing with clinical trials and nanoparticles over the last twenty years (Figure 1).

show abstract

“…The name of this disease is derived from a Greek word meaning "going through" and a Latin word for "honey" or "sweet" [1] and is characterized by the production of a large amount of urine with a honey-like taste [2]. DM is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance [1,[3][4][5]. Nowadays, the number of people suffering from DM and its complications is increasing, in part due to the current worldwide lifestyle: Sedentary lifestyle, high-fat diet, obesity and longer life span [6].…”

Section: Introductionmentioning

confidence: 99%

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I

et al. 2019

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.

show abstract

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II

Cited by 51 publications

References 85 publications

Biological efficacy of zinc oxide nanoparticles against diabetes: a preliminary study conducted in mice

Biological efficacy of zinc oxide nanoparticles against diabetes: a preliminary study conducted in mice

Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I

Contact Info

Product

Resources

About